Details for Patent: 9,211,291
✉ Email this page to a colleague
Which drugs does patent 9,211,291 protect, and when does it expire?
Patent 9,211,291 protects NERLYNX and is included in one NDA.
This patent has fifty-nine patent family members in twenty-nine countries.
Summary for Patent: 9,211,291
Title: | Treatment regimen utilizing neratinib for breast cancer |
Abstract: | An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen. |
Inventor(s): | Berkenblit; Anna (Needham, MA), Binlich; Florence Marie Helene (Ville d'Avray, FR), Goss; Paul (Wellesley, MA) |
Assignee: | WYETH LLC (New York, NY) |
Application Number: | 13/256,910 |
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 9,211,291
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY | ⤷ Try a Trial | ||||
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,211,291
PCT Information | |||
PCT Filed | March 24, 2010 | PCT Application Number: | PCT/US2010/028448 |
PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117633 |
International Family Members for US Patent 9,211,291
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 076197 | ⤷ Try a Trial | |||
Australia | 2010234968 | ⤷ Try a Trial | |||
Brazil | PI1012699 | ⤷ Try a Trial | |||
Canada | 2755789 | ⤷ Try a Trial | |||
China | 102369010 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |